Late-Life Estrogen-Only Therapy Tied to Reduced Dementia and Alzheimer's Signs
A study of over 21,000 participants found that women who used estrogen-only hormone therapy later in life had a lower risk of developing dementia. These women also showed fewer Alzheimer's disease-related brain changes. The findings suggest a potential protective effect of estrogen on cognitive health in older women.
Analyzing a cohort exceeding twenty-one thousand individuals, researchers observed a correlation between initiating estrogen-only hormone replacement during later years and a diminished likelihood of receiving a dementia diagnosis. This association specifically highlighted the late-life window of treatment initiation.
Beyond clinical outcomes, the investigation noted a reduction in neuropathological hallmarks typically associated with Alzheimer's disease among these women. Collectively, these findings point toward a possible safeguarding role for estrogen in preserving cognitive function among the aging female population.
This research could significantly influence clinical decision-making for postmenopausal women, a demographic currently facing complex trade-offs regarding hormone therapy. If the protective effect is confirmed, it may reshape guidelines for late-life estrogen use, potentially offering a preventive strategy against cognitive decline. However, the findings may also prompt broader discussions about individualized risk assessment, as the benefits must be weighed against other health considerations for aging women.